메뉴 건너뛰기




Volumn 15, Issue 19-20, 2010, Pages 826-841

Arginine vasopressin receptor antagonists (vaptans): Pharmacological tools and potential therapeutic agents

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN RECEPTOR; ARGIPRESSIN RECEPTOR BLOCKING AGENT; CONIVAPTAN; HORMONE RECEPTOR BLOCKING AGENT; LIXIVAPTAN; LOOP DIURETIC AGENT; SATAVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

EID: 77957671658     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.08.001     Document Type: Review
Times cited : (28)

References (138)
  • 1
    • 0022637771 scopus 로고
    • Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure
    • Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73:257-267.
    • (1986) Circulation , vol.73 , pp. 257-267
    • Lee, W.H.1    Packer, M.2
  • 2
    • 0021222635 scopus 로고
    • The outcome of hyponatremia in a general hospital population
    • Baran D., Hutchinson T.A. The outcome of hyponatremia in a general hospital population. Clin. Nephrol. 1984, 22:72-76.
    • (1984) Clin. Nephrol. , vol.22 , pp. 72-76
    • Baran, D.1    Hutchinson, T.A.2
  • 3
    • 0033373438 scopus 로고    scopus 로고
    • Vasopressin: a therapeutic target in congestive heart failure?
    • Goldsmith S.R. Vasopressin: a therapeutic target in congestive heart failure?. J. Card. Fail. 1999, 5:347-356.
    • (1999) J. Card. Fail. , vol.5 , pp. 347-356
    • Goldsmith, S.R.1
  • 4
    • 0037823130 scopus 로고    scopus 로고
    • Vasopressin: a new target for the treatment of heart failure
    • Lee C.R., et al. Vasopressin: a new target for the treatment of heart failure. Am. Heart J. 2003, 146:9-18.
    • (2003) Am. Heart J. , vol.146 , pp. 9-18
    • Lee, C.R.1
  • 5
    • 0344013488 scopus 로고    scopus 로고
    • Vasopressin receptor antagonists in heart failure
    • Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr. Opin. Pharmacol. 2003, 3:683-687.
    • (2003) Curr. Opin. Pharmacol. , vol.3 , pp. 683-687
    • Thibonnier, M.1
  • 6
    • 0021163209 scopus 로고
    • Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis
    • Lilly L.S., et al. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J. Clin. Endocrinol. Metab. 1984, 59:924-930.
    • (1984) J. Clin. Endocrinol. Metab. , vol.59 , pp. 924-930
    • Lilly, L.S.1
  • 7
    • 17444383786 scopus 로고    scopus 로고
    • Hyponatremia in congestive heart failure
    • Oren R.M. Hyponatremia in congestive heart failure. Am. J. Cardiol. 2005, 95:2B-7B.
    • (2005) Am. J. Cardiol. , vol.95
    • Oren, R.M.1
  • 8
    • 33645901210 scopus 로고    scopus 로고
    • Hyponatremia and heart failure - treatment considerations
    • Sica D.A. Hyponatremia and heart failure - treatment considerations. Congest. Heart Fail. 2006, 12:55-60.
    • (2006) Congest. Heart Fail. , vol.12 , pp. 55-60
    • Sica, D.A.1
  • 9
    • 0028558373 scopus 로고
    • Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
    • Naitoh M., et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. 1994, 267:H2245-H2254.
    • (1994) Am. J. Physiol. , vol.267
    • Naitoh, M.1
  • 10
    • 0035882341 scopus 로고    scopus 로고
    • The role of V2 vasopressin antagonists in hyponatremia
    • Palm C., et al. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc. Res. 2001, 51:403-408.
    • (2001) Cardiovasc. Res. , vol.51 , pp. 403-408
    • Palm, C.1
  • 11
    • 0028865386 scopus 로고
    • Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism
    • Burrell L.M., et al. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension 1995, 26:828-834.
    • (1995) Hypertension , vol.26 , pp. 828-834
    • Burrell, L.M.1
  • 12
    • 0028298172 scopus 로고
    • Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat
    • Burrell L.M., et al. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994, 23:737-743.
    • (1994) Hypertension , vol.23 , pp. 737-743
    • Burrell, L.M.1
  • 13
    • 0142073812 scopus 로고    scopus 로고
    • Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
    • Gattone V.H., et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 2003, 9:1323-1326.
    • (2003) Nat. Med. , vol.9 , pp. 1323-1326
    • Gattone, V.H.1
  • 14
    • 0027174346 scopus 로고
    • Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats
    • Fujisawa G., et al. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int. 1993, 44:19-23.
    • (1993) Kidney Int. , vol.44 , pp. 19-23
    • Fujisawa, G.1
  • 15
    • 0031001022 scopus 로고    scopus 로고
    • Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    • Saito T., et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J. Clin. Endocrinol. Metab. 1997, 82:1054-1057.
    • (1997) J. Clin. Endocrinol. Metab. , vol.82 , pp. 1054-1057
    • Saito, T.1
  • 16
    • 0020028964 scopus 로고
    • Role of vasopressin in abnormal water excretion in cirrhotic patients
    • Bichet D., et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med. 1982, 96:413-417.
    • (1982) Ann. Intern. Med. , vol.96 , pp. 413-417
    • Bichet, D.1
  • 17
    • 0034122272 scopus 로고    scopus 로고
    • Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension
    • Lacheretz F., et al. Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension. J. Ocul. Pharmacol. Ther. 2000, 16:203-216.
    • (2000) J. Ocul. Pharmacol. Ther. , vol.16 , pp. 203-216
    • Lacheretz, F.1
  • 18
    • 17444400790 scopus 로고    scopus 로고
    • Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure
    • Goldsmith S.R. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am. J. Cardiol. 2005, 95:14B-23B.
    • (2005) Am. J. Cardiol. , vol.95
    • Goldsmith, S.R.1
  • 19
    • 0022911323 scopus 로고
    • Chronic blockade of vasopressin receptors in rats
    • Hofbauer K.G., et al. Chronic blockade of vasopressin receptors in rats. J. Cardiovasc. Pharmacol. 1986, 8(Suppl. 7):S56-S60.
    • (1986) J. Cardiovasc. Pharmacol. , vol.8 , Issue.SUPPL. 7
    • Hofbauer, K.G.1
  • 20
    • 0023945218 scopus 로고
    • Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats
    • Mah S.C., et al. Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 1988, 245:1021-1027.
    • (1988) J. Pharmacol. Exp. Ther. , vol.245 , pp. 1021-1027
    • Mah, S.C.1
  • 21
    • 0021858759 scopus 로고
    • Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure
    • Nicod P., et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am. J. Cardiol. 1985, 55:1043-1047.
    • (1985) Am. J. Cardiol. , vol.55 , pp. 1043-1047
    • Nicod, P.1
  • 22
    • 0031703592 scopus 로고    scopus 로고
    • Recent advances in the understanding of water metabolism in heart failure
    • Schrier R.W., Martin P.Y. Recent advances in the understanding of water metabolism in heart failure. Adv. Exp. Med. Biol. 1998, 449:415-426.
    • (1998) Adv. Exp. Med. Biol. , vol.449 , pp. 415-426
    • Schrier, R.W.1    Martin, P.Y.2
  • 23
    • 0036668564 scopus 로고    scopus 로고
    • Vasopressin V2 receptor antagonists
    • Verbalis J.G. Vasopressin V2 receptor antagonists. J. Mol. Endocrinol. 2002, 29:1-9.
    • (2002) J. Mol. Endocrinol. , vol.29 , pp. 1-9
    • Verbalis, J.G.1
  • 24
    • 0030770540 scopus 로고    scopus 로고
    • Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo
    • Tahara A., et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 1997, 282:301-308.
    • (1997) J. Pharmacol. Exp. Ther. , vol.282 , pp. 301-308
    • Tahara, A.1
  • 25
    • 0031039813 scopus 로고    scopus 로고
    • Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs
    • Yatsu T., et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur. J. Pharmacol. 1997, 321:225-230.
    • (1997) Eur. J. Pharmacol. , vol.321 , pp. 225-230
    • Yatsu, T.1
  • 26
    • 0032981773 scopus 로고    scopus 로고
    • Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats
    • Tomura Y., et al. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin. Exp. Pharmacol. Physiol. 1999, 26:399-403.
    • (1999) Clin. Exp. Pharmacol. Physiol. , vol.26 , pp. 399-403
    • Tomura, Y.1
  • 27
    • 14444285742 scopus 로고    scopus 로고
    • 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors
    • Albright J.D., et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem. 1998, 41:2442-2444.
    • (1998) J. Med. Chem. , vol.41 , pp. 2442-2444
    • Albright, J.D.1
  • 28
    • 0009689526 scopus 로고    scopus 로고
    • Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist
    • Serradeil-Le Gal C., et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. 1996, 98:2729-2738.
    • (1996) J. Clin. Invest. , vol.98 , pp. 2729-2738
    • Serradeil-Le Gal, C.1
  • 29
    • 0032240078 scopus 로고    scopus 로고
    • OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
    • Yamamura Y., et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 1998, 287:860-867.
    • (1998) J. Pharmacol. Exp. Ther. , vol.287 , pp. 860-867
    • Yamamura, Y.1
  • 30
    • 0018460643 scopus 로고
    • Osmotic and nonosmotic control of vasopressin release
    • Schrier R.W., et al. Osmotic and nonosmotic control of vasopressin release. Am. J. Physiol. 1979, 236:F321-F332.
    • (1979) Am. J. Physiol. , vol.236
    • Schrier, R.W.1
  • 31
    • 0023708559 scopus 로고
    • Role of vasopressin in cardiovascular regulation
    • Share L. Role of vasopressin in cardiovascular regulation. Physiol. Rev. 1988, 68:1248-1284.
    • (1988) Physiol. Rev. , vol.68 , pp. 1248-1284
    • Share, L.1
  • 32
    • 0030993733 scopus 로고    scopus 로고
    • Interaction of osmotic and nonosmotic stimuli in regulation of vasopressin secretion in hypoosmolar state of man
    • Kamoi K., et al. Interaction of osmotic and nonosmotic stimuli in regulation of vasopressin secretion in hypoosmolar state of man. Endocr. J. 1997, 44:311-317.
    • (1997) Endocr. J. , vol.44 , pp. 311-317
    • Kamoi, K.1
  • 34
    • 0022020336 scopus 로고
    • Plasma vasopressin response to peripheral administration of angiotensin in conscious rats
    • Yamaguchi K., et al. Plasma vasopressin response to peripheral administration of angiotensin in conscious rats. Am. J. Physiol. 1985, 248:R249-R256.
    • (1985) Am. J. Physiol. , vol.248
    • Yamaguchi, K.1
  • 35
    • 33751036493 scopus 로고    scopus 로고
    • Involvement of anteroventral third ventricular AMPA/kainate receptors in both hyperosmotic and hypovolemic AVP secretion in conscious rats
    • Yamaguchi K., Yamada T. Involvement of anteroventral third ventricular AMPA/kainate receptors in both hyperosmotic and hypovolemic AVP secretion in conscious rats. Brain Res. Bull. 2006, 71:183-192.
    • (2006) Brain Res. Bull. , vol.71 , pp. 183-192
    • Yamaguchi, K.1    Yamada, T.2
  • 36
    • 0018666457 scopus 로고
    • Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin
    • Michell R.H., et al. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. 1979, 7:861-865.
    • (1979) Biochem. Soc. Trans. , vol.7 , pp. 861-865
    • Michell, R.H.1
  • 39
    • 0037623413 scopus 로고    scopus 로고
    • The role of arginine vasopressin and its receptors in the normal and failing rat heart
    • Chandrashekhar Y., et al. The role of arginine vasopressin and its receptors in the normal and failing rat heart. J. Mol. Cell. Cardiol. 2003, 35:495-504.
    • (2003) J. Mol. Cell. Cardiol. , vol.35 , pp. 495-504
    • Chandrashekhar, Y.1
  • 40
    • 0001887593 scopus 로고    scopus 로고
    • The kidneys and body fluids
    • WB Saunders, A.C. Guyton, J.E. Hall (Eds.)
    • Guyton A.C. The kidneys and body fluids. Text Book of Medical Physiology 1996, 308-372. WB Saunders. A.C. Guyton, J.E. Hall (Eds.).
    • (1996) Text Book of Medical Physiology , pp. 308-372
    • Guyton, A.C.1
  • 41
    • 0034637407 scopus 로고    scopus 로고
    • Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor
    • Saito M., et al. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. Eur. J. Pharmacol. 2000, 401:289-296.
    • (2000) Eur. J. Pharmacol. , vol.401 , pp. 289-296
    • Saito, M.1
  • 42
    • 0041965818 scopus 로고    scopus 로고
    • Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas
    • Folny V., et al. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E566-E576.
    • (2003) Am. J. Physiol. Endocrinol. Metab. , vol.285
    • Folny, V.1
  • 43
    • 0033053453 scopus 로고    scopus 로고
    • Physiology and pathophysiology of renal aquaporins
    • Nielsen S., et al. Physiology and pathophysiology of renal aquaporins. J. Am. Soc. Nephrol. 1999, 10:647-663.
    • (1999) J. Am. Soc. Nephrol. , vol.10 , pp. 647-663
    • Nielsen, S.1
  • 44
    • 0001686817 scopus 로고
    • 2O transport in inner medullary collecting duct subsegments
    • 2O transport in inner medullary collecting duct subsegments. Am. J. Physiol. 1987, 253:F823-F832.
    • (1987) Am. J. Physiol. , vol.253
    • Sands, J.M.1
  • 45
    • 0030611357 scopus 로고    scopus 로고
    • V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs
    • Bernat A., et al. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J. Pharmacol. Exp. Ther. 1997, 282:597-602.
    • (1997) J. Pharmacol. Exp. Ther. , vol.282 , pp. 597-602
    • Bernat, A.1
  • 46
    • 0025153828 scopus 로고
    • Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
    • Francis G.S., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
    • (1990) Circulation , vol.82 , pp. 1724-1729
    • Francis, G.S.1
  • 47
    • 0020617013 scopus 로고
    • Increased plasma arginine vasopressin levels in patients with congestive heart failure
    • Goldsmith S.R., et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1983, 1:1385-1390.
    • (1983) J. Am. Coll. Cardiol. , vol.1 , pp. 1385-1390
    • Goldsmith, S.R.1
  • 48
    • 0019861237 scopus 로고
    • Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure
    • Szatalowicz V.L., et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 1981, 305:263-266.
    • (1981) N. Engl. J. Med. , vol.305 , pp. 263-266
    • Szatalowicz, V.L.1
  • 49
    • 0028017360 scopus 로고
    • Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril
    • Rouleau J.L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol. 1994, 24:583-591.
    • (1994) J. Am. Coll. Cardiol. , vol.24 , pp. 583-591
    • Rouleau, J.L.1
  • 50
    • 0030922702 scopus 로고    scopus 로고
    • Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct
    • Nielsen S., et al. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:5450-5455.
    • (1997) Proc. Natl. Acad. Sci. U. S. A. , vol.94 , pp. 5450-5455
    • Nielsen, S.1
  • 51
    • 0030899402 scopus 로고    scopus 로고
    • Upregulation of aquaporin-2 water channel expression in chronic heart failure rat
    • Xu D.L., et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J. Clin. Invest. 1997, 99:1500-1505.
    • (1997) J. Clin. Invest. , vol.99 , pp. 1500-1505
    • Xu, D.L.1
  • 52
    • 0022512331 scopus 로고
    • Hemodynamic effects of infused arginine vasopressin in congestive heart failure
    • Goldsmith S.R., et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. 1986, 8:779-783.
    • (1986) J. Am. Coll. Cardiol. , vol.8 , pp. 779-783
    • Goldsmith, S.R.1
  • 53
    • 0032911139 scopus 로고    scopus 로고
    • AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors
    • Tahara A., et al. AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors. Pflugers Arch. 1999, 437:219-226.
    • (1999) Pflugers Arch. , vol.437 , pp. 219-226
    • Tahara, A.1
  • 54
    • 0033014807 scopus 로고    scopus 로고
    • Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells
    • Tahara A., et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur. J. Pharmacol. 1999, 368:89-94.
    • (1999) Eur. J. Pharmacol. , vol.368 , pp. 89-94
    • Tahara, A.1
  • 55
    • 0032051870 scopus 로고    scopus 로고
    • Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte
    • Tahara A., et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc. Res. 1998, 38:198-205.
    • (1998) Cardiovasc. Res. , vol.38 , pp. 198-205
    • Tahara, A.1
  • 56
    • 0034629529 scopus 로고    scopus 로고
    • Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor
    • Nakamura Y., et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur. J. Pharmacol. 2000, 391:39-48.
    • (2000) Eur. J. Pharmacol. , vol.391 , pp. 39-48
    • Nakamura, Y.1
  • 57
    • 0032971821 scopus 로고    scopus 로고
    • Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor
    • Fukuzawa J., et al. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Cell. Biochem. 1999, 195:93-98.
    • (1999) Mol. Cell. Biochem. , vol.195 , pp. 93-98
    • Fukuzawa, J.1
  • 58
    • 0031405967 scopus 로고    scopus 로고
    • Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells
    • Tahara A., et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J. Cardiovasc. Pharmacol. 1997, 30:759-766.
    • (1997) J. Cardiovasc. Pharmacol. , vol.30 , pp. 759-766
    • Tahara, A.1
  • 59
    • 0037063387 scopus 로고    scopus 로고
    • Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?
    • Spannheimer A., et al. Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?. Praxis (Bern 1994) 2002, 91:1467-1475.
    • (2002) Praxis (Bern 1994) , vol.91 , pp. 1467-1475
    • Spannheimer, A.1
  • 60
    • 0028959755 scopus 로고
    • Torsemide: a pyridine-sulfonylurea loop diuretic
    • Blose J.S., et al. Torsemide: a pyridine-sulfonylurea loop diuretic. Ann. Pharmacother. 1995, 29:396-402.
    • (1995) Ann. Pharmacother. , vol.29 , pp. 396-402
    • Blose, J.S.1
  • 61
    • 0026008394 scopus 로고
    • Torasemide. A review of its pharmacological properties and therapeutic potential
    • Friedel H.A., Buckley M.M. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991, 41:81-103.
    • (1991) Drugs , vol.41 , pp. 81-103
    • Friedel, H.A.1    Buckley, M.M.2
  • 62
    • 0030047538 scopus 로고    scopus 로고
    • Benefits and risks of torasemide in congestive heart failure and essential hypertension
    • Brater D.C. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996, 14:104-120.
    • (1996) Drug Saf. , vol.14 , pp. 104-120
    • Brater, D.C.1
  • 63
    • 17144455013 scopus 로고    scopus 로고
    • Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure
    • López B., et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 2004, 43:2028-2035.
    • (2004) J. Am. Coll. Cardiol. , vol.43 , pp. 2028-2035
    • López, B.1
  • 64
    • 1042302161 scopus 로고    scopus 로고
    • Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life
    • Müller K., et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. Eur. J. Heart Fail. 2003, 5:793-801.
    • (2003) Eur. J. Heart Fail. , vol.5 , pp. 793-801
    • Müller, K.1
  • 65
    • 0036676401 scopus 로고    scopus 로고
    • Torasemide in chronic heart failure: results of the TORIC study
    • Cosín J., Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 2002, 4:507-513.
    • (2002) Eur. J. Heart Fail. , vol.4 , pp. 507-513
    • Cosín, J.1    Díez, J.2
  • 66
    • 0035168346 scopus 로고    scopus 로고
    • Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure
    • Murray M.D., et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am. J. Med. 2001, 111:513-520.
    • (2001) Am. J. Med. , vol.111 , pp. 513-520
    • Murray, M.D.1
  • 67
    • 0031763919 scopus 로고    scopus 로고
    • Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint
    • Spannheimer A., et al. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int. J. Clin. Pract. 1998, 52:467-471.
    • (1998) Int. J. Clin. Pract. , vol.52 , pp. 467-471
    • Spannheimer, A.1
  • 69
    • 0028816616 scopus 로고
    • Torasemide. An update of its pharmacological properties and therapeutic efficacy
    • Dunn C.J., et al. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995, 49:121-142.
    • (1995) Drugs , vol.49 , pp. 121-142
    • Dunn, C.J.1
  • 70
    • 38049043455 scopus 로고    scopus 로고
    • Comparative effects of torasemide and furosemide in rats with heart failure
    • Veeraveedu P.T., et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2008, 75:649-659.
    • (2008) Biochem. Pharmacol. , vol.75 , pp. 649-659
    • Veeraveedu, P.T.1
  • 71
    • 0033592418 scopus 로고    scopus 로고
    • Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
    • Cooper H.A., et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100:1311-1315.
    • (1999) Circulation , vol.100 , pp. 1311-1315
    • Cooper, H.A.1
  • 72
    • 0042354581 scopus 로고    scopus 로고
    • Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)
    • Domanski M., et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 2003, 42:705-708.
    • (2003) J. Am. Coll. Cardiol. , vol.42 , pp. 705-708
    • Domanski, M.1
  • 73
    • 4444234553 scopus 로고    scopus 로고
    • Furosemide and the progression of left ventricular dysfunction in experimental heart failure
    • McCurley J.M., et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J. Am. Coll. Cardiol. 2004, 44:1301-1307.
    • (2004) J. Am. Coll. Cardiol. , vol.44 , pp. 1301-1307
    • McCurley, J.M.1
  • 74
    • 18844423537 scopus 로고    scopus 로고
    • Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study
    • Klein L., et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005, 111:2454-2460.
    • (2005) Circulation , vol.111 , pp. 2454-2460
    • Klein, L.1
  • 75
    • 10344229427 scopus 로고    scopus 로고
    • Risk stratification after hospitalization for decompensated heart failure
    • Felker G.M., et al. Risk stratification after hospitalization for decompensated heart failure. J. Card. Fail. 2004, 10:460-466.
    • (2004) J. Card. Fail. , vol.10 , pp. 460-466
    • Felker, G.M.1
  • 76
    • 34250786282 scopus 로고    scopus 로고
    • Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial
    • Rossi J., et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care 2007, 9:82-86.
    • (2007) Acute Card. Care , vol.9 , pp. 82-86
    • Rossi, J.1
  • 77
    • 0015535785 scopus 로고
    • Synthetic analogs of oxytocin and the vasopressins
    • Sawyer W.H., Manning M. Synthetic analogs of oxytocin and the vasopressins. Annu. Rev. Pharmacol. 1973, 13:1-17.
    • (1973) Annu. Rev. Pharmacol. , vol.13 , pp. 1-17
    • Sawyer, W.H.1    Manning, M.2
  • 78
    • 0021363723 scopus 로고
    • The development of vasopressin antagonists
    • Sawyer W.H., Manning M. The development of vasopressin antagonists. Fed. Proc. 1984, 43:87-90.
    • (1984) Fed. Proc. , vol.43 , pp. 87-90
    • Sawyer, W.H.1    Manning, M.2
  • 79
    • 33745093213 scopus 로고    scopus 로고
    • Vasopressin receptor antagonists
    • Greenberg A., Verbalis J.G. Vasopressin receptor antagonists. Kidney Int. 2006, 69:2124-2130.
    • (2006) Kidney Int. , vol.69 , pp. 2124-2130
    • Greenberg, A.1    Verbalis, J.G.2
  • 80
    • 0022656248 scopus 로고
    • Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system
    • Creager M.A., et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J. Am. Coll. Cardiol. 1986, 7:758-765.
    • (1986) J. Am. Coll. Cardiol. , vol.7 , pp. 758-765
    • Creager, M.A.1
  • 82
    • 0027143189 scopus 로고
    • Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men
    • Ohnishi A., et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. 1993, 92:2653-2659.
    • (1993) J. Clin. Invest. , vol.92 , pp. 2653-2659
    • Ohnishi, A.1
  • 83
    • 0032879771 scopus 로고    scopus 로고
    • In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat
    • Risvanis J., et al. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. Eur. J. Pharmacol. 1999, 381:23-30.
    • (1999) Eur. J. Pharmacol. , vol.381 , pp. 23-30
    • Risvanis, J.1
  • 84
    • 0032988191 scopus 로고    scopus 로고
    • Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
    • Yatsu T., et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur. J. Pharmacol. 1999, 376:239-246.
    • (1999) Eur. J. Pharmacol. , vol.376 , pp. 239-246
    • Yatsu, T.1
  • 85
    • 0036433079 scopus 로고    scopus 로고
    • Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs
    • Yatsu T., et al. Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs. Pharmacol. Res. 2002, 46:375-381.
    • (2002) Pharmacol. Res. , vol.46 , pp. 375-381
    • Yatsu, T.1
  • 86
    • 0037162707 scopus 로고    scopus 로고
    • Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction
    • Wada K., et al. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur. J. Pharmacol. 2002, 450:169-177.
    • (2002) Eur. J. Pharmacol. , vol.450 , pp. 169-177
    • Wada, K.1
  • 87
    • 12344315895 scopus 로고    scopus 로고
    • Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure
    • Wada K., et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur. J. Pharmacol. 2005, 507:145-151.
    • (2005) Eur. J. Pharmacol. , vol.507 , pp. 145-151
    • Wada, K.1
  • 88
    • 0036220502 scopus 로고    scopus 로고
    • Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition
    • Naitoh M., et al. Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc. Res. 2002, 54:51-57.
    • (2002) Cardiovasc. Res. , vol.54 , pp. 51-57
    • Naitoh, M.1
  • 89
    • 0026533435 scopus 로고
    • Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist
    • Yamamura Y., et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 1992, 105:787-791.
    • (1992) Br. J. Pharmacol. , vol.105 , pp. 787-791
    • Yamamura, Y.1
  • 90
    • 0035882211 scopus 로고    scopus 로고
    • Vasopressin V2 receptor antagonists
    • Wong L.L., Verbalis J.G. Vasopressin V2 receptor antagonists. Cardiovasc. Res. 2001, 51:391-402.
    • (2001) Cardiovasc. Res. , vol.51 , pp. 391-402
    • Wong, L.L.1    Verbalis, J.G.2
  • 91
    • 34247198347 scopus 로고    scopus 로고
    • Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials
    • Miyazaki T., et al. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc. Drug Rev. 2007, 25:1-13.
    • (2007) Cardiovasc. Drug Rev. , vol.25 , pp. 1-13
    • Miyazaki, T.1
  • 92
    • 0033965154 scopus 로고    scopus 로고
    • Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats
    • Hirano T., et al. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol. Exp. Ther. 2000, 292:288-294.
    • (2000) J. Pharmacol. Exp. Ther. , vol.292 , pp. 288-294
    • Hirano, T.1
  • 93
    • 0025048502 scopus 로고
    • A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction
    • Kodama M., et al. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin. Immunol. Immunopathol. 1990, 57:250-262.
    • (1990) Clin. Immunol. Immunopathol. , vol.57 , pp. 250-262
    • Kodama, M.1
  • 94
    • 39749187298 scopus 로고    scopus 로고
    • Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure
    • Veeraveedu P.T., et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem. Pharmacol. 2008, 75:1322-1330.
    • (2008) Biochem. Pharmacol. , vol.75 , pp. 1322-1330
    • Veeraveedu, P.T.1
  • 95
    • 35348824902 scopus 로고    scopus 로고
    • Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure
    • Veeraveedu P.T., et al. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. Biochem. Pharmacol. 2007, 74:1466-1475.
    • (2007) Biochem. Pharmacol. , vol.74 , pp. 1466-1475
    • Veeraveedu, P.T.1
  • 96
    • 77954093506 scopus 로고    scopus 로고
    • Effects of tolvaptan (OPC-41061), a vasopressin V2 receptor antagonist, and furosemide on hemodynamics, renal functions, serum electrolytes, and neurohormones in dogs with and without heart failure
    • Onogawa T., et al. Effects of tolvaptan (OPC-41061), a vasopressin V2 receptor antagonist, and furosemide on hemodynamics, renal functions, serum electrolytes, and neurohormones in dogs with and without heart failure. Circulation 2004, 110(Suppl. III):21.
    • (2004) Circulation , vol.110 , Issue.SUPPL. 3 , pp. 21
    • Onogawa, T.1
  • 97
    • 77954751929 scopus 로고    scopus 로고
    • Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure
    • Costello-Boerrigter L.C., et al. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ. Heart Fail. 2010, 3:412-419.
    • (2010) Circ. Heart Fail. , vol.3 , pp. 412-419
    • Costello-Boerrigter, L.C.1
  • 98
    • 22144442803 scopus 로고    scopus 로고
    • Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia
    • Miyazaki T., et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 2005, 146:3037-3043.
    • (2005) Endocrinology , vol.146 , pp. 3037-3043
    • Miyazaki, T.1
  • 99
    • 0029561845 scopus 로고
    • Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats
    • Fujita N., et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am. J. Physiol. 1995, 269:F926-F931.
    • (1995) Am. J. Physiol. , vol.269
    • Fujita, N.1
  • 100
    • 0028286789 scopus 로고
    • Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats
    • Tsuboi Y., et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 1994, 46:237-244.
    • (1994) Kidney Int. , vol.46 , pp. 237-244
    • Tsuboi, Y.1
  • 101
    • 27644574116 scopus 로고    scopus 로고
    • Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention
    • Ros J., et al. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br. J. Pharmacol. 2005, 146:654-661.
    • (2005) Br. J. Pharmacol. , vol.146 , pp. 654-661
    • Ros, J.1
  • 102
    • 0038578522 scopus 로고    scopus 로고
    • Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites
    • Fernández-Varo G., et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J. Hepatol. 2003, 38:755-761.
    • (2003) J. Hepatol. , vol.38 , pp. 755-761
    • Fernández-Varo, G.1
  • 103
    • 0033810608 scopus 로고    scopus 로고
    • Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats
    • Jiménez W., et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J. Pharmacol. Exp. Ther. 2000, 295:83-90.
    • (2000) J. Pharmacol. Exp. Ther. , vol.295 , pp. 83-90
    • Jiménez, W.1
  • 104
    • 0034572628 scopus 로고    scopus 로고
    • Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone
    • Fleeman L.M., et al. Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone. Aust. Vet. J. 2000, 78:825-830.
    • (2000) Aust. Vet. J. , vol.78 , pp. 825-830
    • Fleeman, L.M.1
  • 105
    • 33846068179 scopus 로고    scopus 로고
    • A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    • Wada K., et al. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol. Pharm. Bull. 2007, 30:91-95.
    • (2007) Biol. Pharm. Bull. , vol.30 , pp. 91-95
    • Wada, K.1
  • 106
    • 0020355420 scopus 로고
    • Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats
    • Ishikawa S., Schrier R.W. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats. Kidney Int. 1982, 22:587-593.
    • (1982) Kidney Int. , vol.22 , pp. 587-593
    • Ishikawa, S.1    Schrier, R.W.2
  • 107
    • 0033826077 scopus 로고    scopus 로고
    • Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats
    • Saito T., et al. Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats. Am. J. Physiol. Renal Physiol. 2000, 279:F502-F508.
    • (2000) Am. J. Physiol. Renal Physiol. , vol.279
    • Saito, T.1
  • 108
    • 33646546346 scopus 로고    scopus 로고
    • Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency
    • Wang W., et al. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Am. J. Physiol. Renal Physiol. 2006, 290:F1135-F1142.
    • (2006) Am. J. Physiol. Renal Physiol. , vol.290
    • Wang, W.1
  • 109
    • 0032956538 scopus 로고    scopus 로고
    • Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease
    • Gattone V.H., et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev. Genet. 1999, 24:309-318.
    • (1999) Dev. Genet. , vol.24 , pp. 309-318
    • Gattone, V.H.1
  • 110
    • 1942486801 scopus 로고    scopus 로고
    • Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease
    • Torres V.E., et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 2004, 10:363-364.
    • (2004) Nat. Med. , vol.10 , pp. 363-364
    • Torres, V.E.1
  • 111
    • 44349084391 scopus 로고    scopus 로고
    • Vasopressin antagonists in polycystic kidney disease
    • Torres V.E. Vasopressin antagonists in polycystic kidney disease. Semin. Nephrol. 2008, 28:306-317.
    • (2008) Semin. Nephrol. , vol.28 , pp. 306-317
    • Torres, V.E.1
  • 112
    • 23944515994 scopus 로고    scopus 로고
    • Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat
    • Wang X., et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 2005, 16:846-851.
    • (2005) J. Am. Soc. Nephrol. , vol.16 , pp. 846-851
    • Wang, X.1
  • 113
    • 4644367485 scopus 로고    scopus 로고
    • Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype
    • Yamaguchi T., et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J. Biol. Chem. 2004, 279:40419-40430.
    • (2004) J. Biol. Chem. , vol.279 , pp. 40419-40430
    • Yamaguchi, T.1
  • 114
    • 33746566597 scopus 로고    scopus 로고
    • Increased water intake decreases progression of polycystic kidney disease in the PCK rat
    • Nagao S., et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J. Am. Soc. Nephrol. 2006, 17:2220-2227.
    • (2006) J. Am. Soc. Nephrol. , vol.17 , pp. 2220-2227
    • Nagao, S.1
  • 115
    • 33744963977 scopus 로고    scopus 로고
    • Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    • Ghali J.K., et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 2006, 91:2145-2152.
    • (2006) J. Clin. Endocrinol. Metab. , vol.91 , pp. 2145-2152
    • Ghali, J.K.1
  • 116
    • 34748924247 scopus 로고    scopus 로고
    • Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia
    • Zeltser D., et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol. 2007, 27:447-457.
    • (2007) Am. J. Nephrol. , vol.27 , pp. 447-457
    • Zeltser, D.1
  • 117
    • 33751005260 scopus 로고    scopus 로고
    • Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
    • Schrier R.W., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006, 355:2099-2112.
    • (2006) N. Engl. J. Med. , vol.355 , pp. 2099-2112
    • Schrier, R.W.1
  • 118
    • 33645089230 scopus 로고    scopus 로고
    • Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia
    • Gheorghiade M., et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 2006, 97:1064-1067.
    • (2006) Am. J. Cardiol. , vol.97 , pp. 1064-1067
    • Gheorghiade, M.1
  • 119
    • 77950619540 scopus 로고    scopus 로고
    • Oral tolvaptan is safe and effective in chronic hyponatremia
    • Berl T., et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol. 2010, 21:705-712.
    • (2010) J. Am. Soc. Nephrol. , vol.21 , pp. 705-712
    • Berl, T.1
  • 120
    • 33745689796 scopus 로고    scopus 로고
    • Novel vasopressin V1a and V2 antagonist (conivaptan) increases serum sodium concentration in patients with hyponatremia secondary to congestive heart failure
    • Verbalis J., et al. Novel vasopressin V1a and V2 antagonist (conivaptan) increases serum sodium concentration in patients with hyponatremia secondary to congestive heart failure. J. Card. Fail. 2005, 11(Suppl. 6):S120.
    • (2005) J. Card. Fail. , vol.11 , Issue.SUPPL. 6
    • Verbalis, J.1
  • 121
    • 0037221858 scopus 로고    scopus 로고
    • Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial
    • Russell S.D., et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. 2003, 145:179-186.
    • (2003) Am. Heart J. , vol.145 , pp. 179-186
    • Russell, S.D.1
  • 122
    • 52949114492 scopus 로고    scopus 로고
    • Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study
    • Goldsmith S.R., et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J. Card. Fail. 2008, 14:641-647.
    • (2008) J. Card. Fail. , vol.14 , pp. 641-647
    • Goldsmith, S.R.1
  • 123
    • 0000794014 scopus 로고    scopus 로고
    • Interaction between furosemide and oral conivaptan (YM087) in patients with heart failure
    • Tonkon M., et al. Interaction between furosemide and oral conivaptan (YM087) in patients with heart failure. Eur. Heart J. 2001, 22:541.
    • (2001) Eur. Heart J. , vol.22 , pp. 541
    • Tonkon, M.1
  • 124
    • 0037904417 scopus 로고    scopus 로고
    • Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial
    • Gheorghiade M., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690-2696.
    • (2003) Circulation , vol.107 , pp. 2690-2696
    • Gheorghiade, M.1
  • 125
    • 11144355788 scopus 로고    scopus 로고
    • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    • Gheorghiade M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. J. Am. Med. Assoc. 2004, 291:1963-1971.
    • (2004) J. Am. Med. Assoc. , vol.291 , pp. 1963-1971
    • Gheorghiade, M.1
  • 126
    • 33947719178 scopus 로고    scopus 로고
    • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    • Gheorghiade M., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J. Am. Med. Assoc. 2007, 297:1332-1343.
    • (2007) J. Am. Med. Assoc. , vol.297 , pp. 1332-1343
    • Gheorghiade, M.1
  • 127
    • 33947713810 scopus 로고    scopus 로고
    • Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    • Konstam M.A., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. J. Am. Med. Assoc. 2007, 297:1319-1331.
    • (2007) J. Am. Med. Assoc. , vol.297 , pp. 1319-1331
    • Konstam, M.A.1
  • 128
    • 20944445209 scopus 로고    scopus 로고
    • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    • Gheorghiade M., et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail. 2005, 11:260-269.
    • (2005) J. Card. Fail. , vol.11 , pp. 260-269
    • Gheorghiade, M.1
  • 129
    • 0035856509 scopus 로고    scopus 로고
    • Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure
    • Udelson J.E., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417-2423.
    • (2001) Circulation , vol.104 , pp. 2417-2423
    • Udelson, J.E.1
  • 130
    • 54349103474 scopus 로고    scopus 로고
    • Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial
    • Udelson J.E., et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 2008, 52:1540-1545.
    • (2008) J. Am. Coll. Cardiol. , vol.52 , pp. 1540-1545
    • Udelson, J.E.1
  • 131
    • 34249325160 scopus 로고    scopus 로고
    • Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
    • Udelson J.E., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 2007, 49:2151-2159.
    • (2007) J. Am. Coll. Cardiol. , vol.49 , pp. 2151-2159
    • Udelson, J.E.1
  • 132
    • 33644867235 scopus 로고    scopus 로고
    • Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
    • Costello-Boerrigter L.C., et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. 2006, 290:F273-F278.
    • (2006) Am. J. Physiol. Renal Physiol. , vol.290
    • Costello-Boerrigter, L.C.1
  • 133
    • 38349099530 scopus 로고    scopus 로고
    • Acute hemodynamic effects of tolvaptan, a Vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multicenter, randomized, placebo-controlled trial
    • Udelson J.E., et al. Acute hemodynamic effects of tolvaptan, a Vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multicenter, randomized, placebo-controlled trial. J. Card. Fail. 2007, 13:793-794.
    • (2007) J. Card. Fail. , vol.13 , pp. 793-794
    • Udelson, J.E.1
  • 135
    • 24944563849 scopus 로고    scopus 로고
    • American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
    • Hunt S.A. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Website. J. Am. Coll. Cardiol. 2005, 46:e1-e82.
    • (2005) J. Am. Coll. Cardiol. , vol.46
    • Hunt, S.A.1
  • 136
    • 35848944656 scopus 로고    scopus 로고
    • Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials
    • McMurray J.J., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. J. Am. Med. Assoc. 2007, 298:2009-2019.
    • (2007) J. Am. Med. Assoc. , vol.298 , pp. 2009-2019
    • McMurray, J.J.1
  • 137
    • 11144355760 scopus 로고    scopus 로고
    • Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
    • Mann D.L., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
    • (2004) Circulation , vol.109 , pp. 1594-1602
    • Mann, D.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.